Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04911478 · ClinicalTrials.gov registry record
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
A clinical trial, sponsored by Adicet Therapeutics.
- Active
- Registry status
- 50
- Enrollment target
NCT04911478: Active study, sponsored by Adicet Therapeutics.
NCT04911478 is a clinical trial that is active but no longer recruiting, run by Adicet Therapeutics. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04911478 is active but no longer recruiting, sponsored by Adicet Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to assess long-term side effects from subjects who receive an Adicet Bio γδ CAR T cell product. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years from the first administration of Adicet Bio allogeneic γδ CAR T cell product, subjects will be assessed for long-term safety and survival through collection of data that include safety, efficacy, pharmacokinetics and immunogenicity.
Primary Outcome
Occurrence of new Adverse Events of Special interests, Serious AEs and malignancies
Interventions
- GENETIC ADI-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-02-14 |
| Est. Completion | 2039-08 |
What the registry record for NCT04911478 still lists
NCT04911478 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which ADI-001 is the first listed.
NCT04911478 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04911478 about?
NCT04911478 is a clinical study titled "Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells". The purpose of this study is to assess long-term side effects from subjects who receive an Adicet Bio γδ CAR T cell product. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their ca...
What is the current status of trial NCT04911478?
This trial is currently active not recruiting. The enrollment target is 50 participants. The study started on 2022-02-14. Estimated completion is 2039-08.
What interventions are being tested in trial NCT04911478?
The interventions under investigation include: ADI-001 (GENETIC).
Who is sponsoring clinical trial NCT04911478?
This trial is sponsored by Adicet Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI